These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1238 related articles for article (PubMed ID: 26918392)

  • 1. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
    Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation.
    Ferguson KT; Torr EE; Bernau K; Leet J; Sherris D; Sandbo N
    J Cell Biochem; 2017 Aug; 118(8):2241-2249. PubMed ID: 28078713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
    Mecca C; Giambanco I; Donato R; Arcuri C
    Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
    Hu X; Wang Z; Chen M; Chen X; Liang W
    Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
    Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
    PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting 4EBP1 in Glioblastoma.
    Fan QW; Nicolaides TP; Weiss WA
    Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma.
    Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M
    Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.